Laurence Katznelson, MD
Endocrinology, Diabetes & Metabolism · Los Angeles, CANPI 1013082643
Payments from drug & device makers
Across 66 payments — averaging $2851.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascendis Pharma Endocrinology Inc$83K
- Corcept Therapeutics$37K
- Novo Nordisk$28K
- Novartis$10K
- Recordati_rare_diseases_inc.$9K
- Xeris Pharmaceuticals, Inc.$5K
- plus $17K from 8 others
What the payments were for
- Consulting fees$55,60656%
- Speaking & faculty fees$38,97539%
- Travel & lodging$3,9864%
- Food & beverage$6581%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascendis Pharma Endocrinology Inc | 11 | $82,910 |
| Corcept Therapeutics | 10 | $36,620 |
| Novo Nordisk | 28 | $27,876 |
| Novartis | 2 | $10,357 |
| Recordati_rare_diseases_inc. | 3 | $8,900 |
| Xeris Pharmaceuticals, Inc. | 1 | $4,900 |
| AstraZeneca | 3 | $3,589 |
| Ipsen Biopharmaceuticals, Inc | 2 | $3,440 |
| Ipsen Innovation | 1 | $3,010 |
| Ipsen Biopharm Limited | 1 | $2,365 |
| HRA Pharma RARE Diseases | 1 | $2,000 |
| Strongbridge US Inc. | 1 | $1,800 |
| Mallinckrodt LLC | 1 | $375 |
| Chiesi USA, Inc. | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$36,464
- Norditropin$18,963
- SOMATULINE DEPOT$5,805
- METOPIRONE$2,000
How this compares
$188,177 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocortisone | 14 | $161 |
| Levothyroxine Sodium | 12 | $67 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Los Angeles
- Stanley HsiaLos Angeles$19.8M
- Shlomo MelmedLos Angeles$3.3M
- Sina TebiLos Angeles$2.4M
- Anthony HeaneyLos Angeles$788K
- Christian GastelumLos Angeles$421K
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.